Yousif Capital Management LLC Reduces Stock Position in Pfizer Inc. $PFE

Yousif Capital Management LLC lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 7.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 576,096 shares of the biopharmaceutical company’s stock after selling 43,746 shares during the quarter. Yousif Capital Management LLC’s holdings in Pfizer were worth $14,702,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. Brighton Jones LLC boosted its stake in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after buying an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC boosted its stake in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after buying an additional 2,087 shares during the last quarter. United Bank boosted its stake in shares of Pfizer by 12.4% in the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after buying an additional 6,415 shares during the last quarter. Cary Street Partners Investment Advisory LLC boosted its holdings in shares of Pfizer by 79.1% in the second quarter. Cary Street Partners Investment Advisory LLC now owns 4,941 shares of the biopharmaceutical company’s stock worth $120,000 after buying an additional 2,182 shares during the last quarter. Finally, Transce3nd LLC boosted its holdings in shares of Pfizer by 59.4% in the second quarter. Transce3nd LLC now owns 1,879 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 700 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of NYSE:PFE opened at $27.10 on Wednesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $28.75. The company has a market capitalization of $154.07 billion, a P/E ratio of 19.92 and a beta of 0.43. The firm’s 50 day simple moving average is $27.14 and its two-hundred day simple moving average is $25.89.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter in the previous year, the firm earned $0.63 earnings per share. The company’s revenue for the quarter was down 1.2% on a year-over-year basis. Research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently issued reports on PFE. Bank of America dropped their price objective on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a report on Monday, December 15th. BMO Capital Markets reissued an “outperform” rating and issued a $30.00 price objective on shares of Pfizer in a report on Monday, March 9th. Cantor Fitzgerald reiterated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research report on Wednesday, February 4th. Zacks Research upgraded Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Finally, Wolfe Research set a $24.00 price objective on Pfizer and gave the stock an “underperform” rating in a research note on Wednesday, December 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $28.19.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.